Vertex Reports Second-Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vertex (VRTX) PT Raised to $203 at RBC Capital
July 26, 2018 8:44 AM EDTRBC Capital raised its price target on Vertex (NASDAQ: VRTX) to $203.00 (from $202.00) while maintaining an Outperform rating.
Analyst Brian Abrahams commented, "Despite rising expectations into 2Q, an impressive beat for VRTX's CF franchise."
... MoreVertex (VRTX) PT Raised to $204 at BMO Capital; 'Stellar Revenue'
July 26, 2018 7:11 AM EDTBMO Capital raised its price target on Vertex (NASDAQ: VRTX) to $204.00 (from $191.00) while maintaining an Outperform rating following results.
Analyst Do Kim commented, "We raise our revenue estimates and target price to $204 from $191, following stellar 2Q18 CF revenues that easily exceeded our and... More
Vertex (VRTX) PT Raised to $200 at Oppenheimer
July 26, 2018 6:59 AM EDTOppenheimer raised its price target on Vertex (NASDAQ: VRTX) to $200.00 (from $180.00) while maintaining an Outperform rating following results.
Analyst Hartaj Singh commented, "Vertex (VRTX) reported 2Q18 sales/earnings and provided a business update to investors on 7/25. Based on the company's robust results and... More
Vertex Pharma (VRTX) Tops Q2 EPS by 19c; Raises Outlook
July 25, 2018 4:03 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $0.94, $0.19 better than the analyst estimate of $0.75. Revenue for the quarter came in at $750 million versus the consensus estimate of $680.98 million.
Company increases full-year 2018 total CF product revenue guidance to $2.9 to $3.0 billion; reiterates full-year 2018... More
